Malta - English - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - salmeterol xinafoate, fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg fluticasone propionate 125 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - salmeterol xinafoate, fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg fluticasone propionate 250 µg - drugs for obstructive airway diseases

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy. for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy. for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy.*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fluticasone propionate,salmeterol xinafoate -

United States - English - NLM (National Library of Medicine)

prasco laboratories - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u), salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - fluticasone propionate and salmeterol hfa is indicated for treatment of asthma in adult and adolescent patients aged 12 years and older. fluticasone propionate and salmeterol hfa should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). limitations of use fluticasone propionate and salmeterol hfa is not indicated for the relief of acute bronchospasm. fluticasone propionate and salmeterol hfa is contraindicated in the following conditions: risk summary there are insufficient data on the use of fluticasone propionate and salmeterol hfa or individual monoproducts, fluticasone propionate and salmeterol xinafoate, in pregnant women. there are clinical considerations with the use of fluticasone propionate and salmeterol hfa in pregnant women. (see clinical considerations.) in animals, teratogenicity characteristic of cortic

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/250 microgram(s)/dose - salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/50 microgram(s)/dose - salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - salmeterol xinafoate ; fluticasone propionate - pressurised inhalation suspension - 25mcg/125 microgram - salmeterol and fluticasone